Sažetak
Aim: Paraoxonase 1 (PON1) is a calcium-dependent esterase and exerts antioxidant and anti-atherogenic properties. Advanced oxidation protein products (AOPP) are a group of carbonylated protein products showing oxidant-mediated protein damage. This study aimed to determine serum PON1 activities and AOPP concentrations in diabetic patients and to evaluate these parameters in terms of their relationships with diabetes mellitus (DM) and related factors.
Methods: A total of 93 patients diagnosed with type 2 DM and 30 healthy controls were enrolled in the study. Serum AOPP levels and PON1 activities were measured spectrophotometrically. Other measurements and clinical/demographic data were ordered for all patients, measured in the routine blood chemistry laboratory, and retrieved from patient files.
Results: Serum PON1 activity was significantly lower in patients with DM (31.6 [21.49-48.45] U/mL) compared to controls (41.08 [29.07-54.35] U/mL) (p=0.028). Serum AOPP concentration was significantly higher in diabetic patients (584.6 [453.8-778.6] µmol/L) than in controls (173.9 [98.77-224.1] µmol/L) (p<0.001). PON1 activity negatively correlated with AOPP concentration, and positively with serum HDL-1 levels. AOPP concentration positively correlated with age, weight, HbA1c, glucose, total cholesterol, and LDL-C. A PON1 activity cut-off of ≤25 U/mL predicted DM with a sensitivity of 36.56% and specificity of 90% (AUC: 0.634, p=0.028). An AOPP concentration cut-off of >340 µmol/L predicted DM with a sensitivity of 89.25% and specificity of 93.33% (AUC: 0.965). Both PON1 (OR: 10.821, 95% CI: 1.959 - 59.778, p=0.006) and AOPP (OR: 190.068, 95% CI: 20.102 - 1797.148, p<0.001) were independently associated with DM after adjusting for age, sex, and weight.
Conclusions: AOPP and PON1 may play a significant role in the development and progression of DM. Particularly serum AOPP concentrations appear to be distinctive among patients with new-onset DM.
Ključne reči
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.